Ensuring Pharmaceutical Accountability for Human Rights and Access to Medicines
The Dutch Duty of Care Standard Applied to Pharmaceutical Companies
Bibliographic Data
| ID | 6436014 |
|---|---|
| Authors | Rosalind Turkie (0000-0002-0282-1131), Katrina Perehudoff (0000-0003-3958-0244), Jennifer Sellin, Aldo Sainz |
| Year | 2024 |
| Volume | 17 |
| Issue | 1 |
| Pages | 154-176 |
| Publication date | 2024-12-10 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Journal of Human Rights Practice (JOURNAL) |
| Journal identifiers | ISSN: 1757-9619 • E-ISSN: 1757-9627 |
| Publisher | Oxford University Press (OUP) (PUBLISHER) |
| DOI | 10.1093/jhuman/huae046 |
| OpenAlex | W4405218999 |
| Language | EN |
| References cited | 21 |
To effectively protect the human right to health, the global accountability gap for pharmaceutical companies regarding access to medicines must be addressed. Pharmaceutical companies have no formal obligations under human rights law; however, they do have responsibilities, and some companies (directly or indirectly) undermine the right to health and equitable access to medicines. We propose that pharmaceutical companies can be held accountable for human rights interferences by means of a provision in Dutch tort law containing an ‘unwritten duty of care’, an interpretation which is supported by the international human rights framework and recent Dutch jurisprudence. We propose a concrete example of how this duty could be applied in Dutch courts, which have previously held a private corporation accountable for contributing to dangerous climate change in the Milieudefensie et al. v Royal Dutch Shell case. To establish whether this duty could be applied to pharmaceutical companies, we use the court’s reasoning in Milieudefensie to assess the existence of a global consensus on the need for a pharmaceutical duty of care. We argue that human rights norms and soft law instruments that pharmaceutical companies themselves have endorsed prove that there is a growing consensus regarding the damage associated with excessively priced medicines, and an urgent need to establish a framework for holding pharmaceutical companies accountable for ensuring equitable access to medicines through legal measures
Accountability · Business · Corporation · Duty · Duty of care · Economics · Essential medicines · Health care · Human rights · Law and economics · Liability · Pharmaceutical industry · Political science · Right to health · Tort · Human Rights and Development · Intellectual Property and Patents · Medicine · Pharmaceutical Economics and Policy · Accounting · Finance · Law · Pharmacology
Essential medicines for universal health coverage
Overriding drug and medical technology patents for pandemic recovery
Universal access to essential medicines as part of the right to health
Raising the Barriers to Access to Medicines in the Developing World – The Relentless Push for Data Exclusivity
South Africa's Treatment Action Campaign
A human rights-based, regime interaction approach to climate change and malnutrition
Legislating for universal access to medicines
Business and Human Rights
The Duty of Care of Fossil-Fuel Producers for Climate Change Mitigation
An Apology Leading to Dystopia
| Citation velocity | historical |
|---|---|
| Highly cited | No |